The FDA has approved Starjemza (ustekinumab-hmny), a biosimilar to Stelara (ustekinumab), for the treatment of various chronic inflammatory diseases.

The U.S. Food and Drug Administration (FDA) already declared that shortages of popular GLP-1 medications have ended, CNN reported. Those medications include semaglutide (Ozempic and Wegovy) and ...

The Food and Drug Administration has designated Hadlima (adalimumab-bwwd) an interchangeable biosimilar to Humira (adalimumab).

The disease burden of atopic dermatitis was high in pediatric patients, but factors affecting the burden differed between adolescents and children.

Bimekizumab use for 4 years among patients with plaque psoriasis is associated with sustained efficacy outcomes and no new safety signals.

Patients with varicose veins have a higher risk for all-cause dementia, while treatment of varicose veins is tied to a lower risk for vascular dementia.

Conversations in Dermatology: 2025 will focus on clinical challenges and recent advances that health care providers who manage chronic pruritic conditions should know.

A new COVID-19 variant, NB.1.8.1, has spread in the Mediterranean, Southeast Asia, and Western Pacific regions.

Anti-OX40 medications have been associated with positive efficacy and safety outcomes for the treatment of atopic dermatitis.

Patients with uveitis had a higher risk for psoriatic arthritis and psoriasis, whereas those with psoriatic arthritis had a higher risk for uveitis.

The Food and Drug Administration has approved Zoryve (roflumilast) topical foam, 0.3% for plaque psoriasis of the scalp and body.

The FDA has announced its plan for systematically reviewing food additives already commercially available for the first time.